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Abstract Mutants of human prothymosin a with impaired 
ability to inhibit yeast Saccharomyces cerevisiae. cerevisiae cell 
growth were characterized. Two types of prothymosin oc-in-
activating mutations were observed. Mutations that belong to the 
first type compromised the nuclear entry of prothymosin a by 
affecting its nuclear localization signal. Analysis of subcellular 
distribution of GFP-prothymosin a fusions revealed a bipartite 
nuclear localization signal that is both necessary and sufficient 
for nuclear import of the protein in human cells. Mutations of the 
second type abrogated the inhibitory action of prothymosin a 
through an unknown mechanism, without influencing the nuclear 
import of the protein. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Prothymosin a (ProToc) is an abundant highly acidic pro-
tein of 13 k D a with an unknown but essential function [1-5]. 
ProToc was originally isolated from thymus and was believed 
to serve as a precursor of the putative thymic hormone thy-
mosin on, hence its name [1]. However, several features of 
ProToc, in particular its wide tissue distribution [6] and its 
ability to accumulate in the nucleus [7-10], suggest an intra-
nuclear function of this protein. Accumulating evidence sug-
gests that P r o T a may be related to proliferation of mamma-
lian cells. Elevated levels of ProTcx were observed in 
proliferating cells [11,12]. The growth stimulation of quiescent 
mammalian cells results in an abrupt increase of ProTa gene 
expression [3]. The levels of P r o T a and its m R N A , however, 
do not appear to vary significantly in the cell cycle [5,13,14]. A 
unique functional ProTa-encoding gene was characterized in 
the mammalian cells [15,16]. Its expression was reported to be 
stimulated by M Y C oncoprotein [17,18], though some contro-
versy exists concerning the regulation of transcription of the 
ProTa gene by M Y C [19]. The inhibition of P r o T a synthesis 
by antisense oligonucleotides led to the cessation of cell divi-
sion [4]. 
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Although these data suggest a correlation between cell pro-
liferation and P r o T a expression, the function and the mech-
anism of action of P r o T a are unknown. In this work, we 
functionally dissected human ProTa . We used a recently de-
scribed yeast genetic screen [20,21] to isolate a panel of novel 
P r o T a mutat ions that affect the ability of the protein to in-
hibit yeast cell growth. Our results show that a subset of 
mutat ions that impaired the ability of P r o T a to inhibit yeast 
cell growth led to impaired nuclear import by affecting the 
NLS. This suggests that nuclear localization may be a prereq-
uisite of the inhibitory phenotype of human P r o T a in yeast. 
Another mutat ion, T105A, showed a low level of cell growth 
inhibition, but did not affect the nuclear localization of the 
protein in yeast cells, suggesting that Th r l05 residue may be 
directly involved in the inhibitory phenotype of P roTa . The 
subcellular localization data obtained in this study led to the 
characterization of the NLS of P roTa , which consists of two 
blocks of basic residues and, therefore, belongs to a group of 
bipartite NLS . 
2. Materials and methods 
2.1. ProTa mutagenesis and clone selection 
E. coli JM109 and S. cerevisiae 2805 [MATa, pep4::His3, prb 1-5, 
canl, Gal2, his38, ura3-52] strains were used throughout this work. 
Standard procedures for DNA cloning were used. Conditions for 
PCR-based random mutagenesis of the human ProTa using pHT15 
[22] as a template were as described [21]. The PCR products were 
digested with BamHl and EcoRl, and inserted into the BamHl-
ZicoRI-digested pYeDP 1/8-2 yeast shuttle vector [23] to produce 
pYeM series of plasmids. Yeast cells were transformed by the 
DMSO-lithium acetate method [24] and plated on a glucose-contain-
ing SD medium (2% glucose, 0.67% yeast nitrogen base, 0.1% cas-
amino acids). For selection, the resultant colonies were transferred on 
a nitrocellulose membrane to galactose-containing S5 plates (2% gal-
actose, 0.67% yeast nitrogen base, 0.1% casamino acids). DNA from 
yeast cells that survived in the presence of mutated ProTa was iso-
lated by the method described in [25] and used to transform bacterial 
cells for subsequent sequencing and rearranging of plasmid inserts 
utilizing unique Acyl and Ddel sites in the ProTa cDNA [21]. Plas-
mids with single or double mutations in ProTa cDNA were retrans-
formed into yeast cells, and cell growth parameters were measured in 
the galactose-containing S5 liquid medium. The procedure for ProTa 
isolation from yeast cells was described [20]. 
2.2. Construction of GFP-ProTa fusion proteins 
pGFP-C2 (Clontech) was used for constructing GFP-ProTa fu-
sions and their production in human cells. To produce GFP-ProTa 
fusion proteins in yeast cells, a complete GFP gene with polylinker as 
a 1100 bp Ncol-MM fragment of pGFP-C2 (partially digested with 
Ncol to preserve complete reading frame of GFP) was blunt-ended by 
the Klenow fragment in the presence of dNTP and inserted into the 
filled-in BamHI site of pYeDPl/8-2 vector to yield pYeGFP. ProTa 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / / S 0 0 1 4 - 5 7 9 3 ( 9 7 ) 0 0 8 2 4 - 7 
136 Y.P. Rubtsov et al.lFEBS Letters 413 (1997) 135-141 
cDNAs with denned mutations were excised from the rearranged 
pYeM derivatives with BamHI and EcoRI and inserted into the 
Bglll-EcoRl digested pGFP-C2 and pYeGFP in-frame with GFP. 
cDNAs encoding wild-type and A(101-109) ProTa were excised 
from pHT15 [22] and pYeKHTl [20], respectively, with BamHI and 
EcoRI and ligated into pGFP-C2 and pYeGFP in analogous fashion. 
To construct GFP-(82-109) fusion protein, pGFP-C2 and pYeGFP 
were digested with EcoRI, filled-in with the KJenow fragment, cut 
with Kpnl and ligated with the NLS-encoding DNA fragment ob-
tained as follows. A BamHI-EcoRI cDNA fragment encoding wild-
type ProTa was hydrolyzed with Ddel, filled-in with the Klenow frag-
ment and recleaved with Kpnl. The resultant 90 bp fragment was 
inserted into the vectors in-frame with GFP. The structure of plasmids 
was verified by sequencing. 
2.3. Fluorescent microscopy of the ProTa-producing cells 
A human embryonic kidney cell line, 293, was transiently trans-
fected by calcium precipitate method [26]. Plasmids were purified on 
QIAGEN columns according to the manufacturer's instructions. Five 
micrograms of GFP-ProTa expression plasmids was used without 
carrier DNA per 60-mm gelatin-coated glass-bottom culture dish, 
and fluorescent microscopy was performed at Day 1 post-transfection. 
Images were captured to a SenSys CCD camera (Photometries) 
mounted on a Zeiss Axiovert 135 TV inverted microscope, using Zeiss 
Achroplan 40 X water-immersion objective lens. 
Yeast S. cerevisiae 2805 cells transformed with the ProTa-encoding 
derivatives of pYeGFP were grown in SD medium overnight at 30°C. 
Cells were collected by centrifugation, resuspended in S5 medium to 
induce transcription of the target gene, and grown overnight at 30°C. 
Cells were removed from the culture and molded in 0.5% low-melting 
point agarose on a glass slide. Fluorescent microscopy was performed 
with a Zeiss Photomicroscope 3 equipped with a Neofluar 100X oil-
immersion lens. 
Aliquots of galactose-induced yeast cells producing various GFP 
ProTa fusions were processed for PAGE. Lysates were made in a 
buffer containing 0.1 M Tris-HCl, pH 8.0, 0.2 M NaCl, 10 mM 
P-mercaptoethanol, 5 mM EDTA, 20% glycerol and 1 mM PMSF 
by glass bead lysis, and then centrifuged at 15000Xg for 3 min. 
Sample buffer was added to the supernatants, a boiling step was 
omitted, and samples were resolved by SDS-PAGE on 15% gels 
[27]. Positions of GFP-ProTa bands were visualized by UV illumina-
tion of the gels at 302 nm. 
3. Results 
3.1. Amino acid residues essential for yeast cell growth 
inhibition reside in the carboxy-terminal region of 
human ProTa 
To define functionally important amino acid residues in 
human ProTa, we used the recently described approach [21] 
which included random mutagenesis with subsequent produc-
tion of various mutant forms of ProTa and evaluation of 
their properties in yeast S. cerevisiae. The randomly mutagen-
ized ProTa cDNAs were cloned into a yeast expression vector 
under the control of a strong galactose-inducible promoter. 
The resultant plasmids were introduced into yeast cells for an 
in vivo genetic screen for mutations that adversely affect 
ProTa activity. The screen is based on a severe inhibition of 
yeast cell growth by wild-type human ProTa. By using this 
approach, a number of mutant ProTa-producing yeast clones 
that gained the ability to grow were selected. ProTa produced 
by each of these clones turned out to possess several amino 
acid substitutions that are listed in Table 1. In order to eval-
uate the contribution of particular mutations to the observed 
growth phenotype, single or double mutations were recovered 
by DNA shuffling. In addition, a ProTa mutant with several 
substitutions grouped in the amino-terminal portion of the 
molecule was generated (Table 1). Production of these ProTa 
mutants in yeast cells was verified by SDS-PAGE (Fig. 1). For 
each mutant, similar amounts of protein were produced. 
To quantitate ProTa inactivation, growth parameters of the 
yeast cells bearing plasmids encoding the wild-type and mu-
tant ProTa were determined in the liquid medium. The results 
of this assay are shown in Fig. 2A. While in the absence of the 
inducer of human ProTa production all types of cells grew 
equally well (not shown), growth parameters of the strains 
producing various ProTa mutants in the presence of galactose 
turned out to be different. As expected, the wild-type ProTa 
efficiently blocked cell growth. Interestingly, multiple muta-
tions in the amino-terminal portion of ProTa SIP, IIIV, 
K14W, K17E (Fig. 2A, empty circles); SIT; K14E, E24G 
(not shown), solely or in combination, did not abrogate the 
inhibitory action of the protein. Substituting Gly75 for Val, 
which converts the sequence of our wild-type ProTa clone to 
those described in [2,3] also had no effect (not shown). How-
ever, the mutations in the carboxy-terminal part of ProTa 
resulted in various degrees of inactivation. Thus, the T105A 
mutant showed a low level of cell growth inhibition. Single 
E80G and K101R mutations each resulted in approximately 
50% reduction, but the respective double mutant was virtually 
inactive. The double mutant E44G, E50G showed approxi-
mately 50% reduction. The results of these experiments, to-
gether with our earlier data on K87E inactivating mutation 
[21] are summarized in Fig. 2B. It should be noted that dele-
tion of the last nine amino acid residues of ProTa resulted in 
complete loss of the inhibitory phenotype [20]. From these 
data we conclude that a number of residues essential for cell 
growth inhibition are located in the carboxy-terminal portion 
of ProTa, while multiple mutations in the amino-terminal 
region of the protein are well tolerated. 
3.2. NLS of human ProTa is bipartite 
We next addressed the mechanism by which the mutations 
Table 1 
Human ProTa mutants generated in this study 
Primary mutants Mutants subjected to analysis 
SIP, IIIV, K14W, K17E, A38V, E55G, D93G, K101R, K104E 
K14E, E24G, E80G, E91G, E94G, K101E 
E44G, E50G, T105A 
SIT, N39D, K87E 
E80G, K101R 
1 
2 
3 
4 
5 
6 
7 
8 
SIP, 11IV, K14W, K17E 
K14E, E24G 
E44G, E50G 
T105A 
SlTa 
K87Ea 
E80G 
K101R 
Left column: primary mutants with multiple amino acid substitutions obtained via the screening procedure. 
Right column: single and double ProTa mutants obtained through the rearrangement of cDNAs of primary mutants. 
aProTa mutants that were characterized earlier [21]. 
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Fig. 1. Production of wild-type human ProTa and various mutants in yeast. Analysis of ProTa and its mutants produced in yeast cells. Ex-
tracts of cells induced with galactose were resolved in 8% PAGE followed by methylene blue staining [20]. The positions of ProTa and tRNA 
are indicated. Lanes 1: wild-type ProTa; lane 2: E80G mutant; lane 3: K101R mutant; lane 4: E80G, K101R double mutant; lane 5: 
A(101-109) mutant [20]; lane 6: K87E mutant [21]; lane 7: E44G, E50G double mutant; lane 8: T105A mutant; lane 9: SIP, I l lV, K14W, 
K17E mutant. 
in P r o T a affect cell growth inhibition. Previous studies led us 
to hypothesize that the nuclear import of P r o T a is a prere-
quisite for its inhibitory action on yeast cell growth and that 
mutat ions that affect the putative N L S of P r o T a relieve this 
Table 2 
Analysis of the human ProTa NLS 
Protein 
Nucleoplasmin 
NLS 
Human ProTa 
K87E 
K101R 
T105A 
A (101-109) 
NLS (82-109) 
Amino acid sequence 
-KR - 10 aa spacer - KKKK-
155 170 
- A E S A T G K R 7 \ A E D D E D D D V D T K K Q K T D E D D C O O H 
82 87 101 109 
- • • • • • • E * * * * * + * * * * * * * * * * * * * * * 
- • • • • • • • • • • • • • • • • • • • R * * * * * * * - * -
- • • • • • • • • • • • • • • • • • • • • • • • A * * + ^ 
- • • • • • • • • * • • • • • • • • • • 
* * • • • * * * * • + * * * ■ * ■ • * • * * • • * * * * * 
Yeast growth 
inhibition 
+ 
-
+ / -
-
-
n. d. 
Intracellular 
localization 
nuc 
nuc 
nuc > cyt 
nuc > cyt 
nuc(y) 
cyt (h) 
nuc > cyt(y) 
nuc(h) 
nuc = cyt(y) 
The amino acid sequence of human ProTa between residues 81 and 109 is shown, aligned with the bipartite nucleoplasmin NLS sequence [28]. 
Basic residues essential for nucleoplasmin NLS functioning and corresponding ProTa residues are in bold. The sequences of various ProTa mu-
tants are given below; an asterisk marks a residue identical with that in the wild-type protein; substitutions are shown by indicating the new 
residue. The columns on the right show the ability (+) or inability (—) of the protein to inhibit yeast cell growth, and indicate subcellular local-
ization of the corresponding GFP-ProTa fusions, respectively, (h) and (y) corresponds to protein localization in human and yeast cells, respec-
tively. n.d., not determined. 
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Fig. 2. A: Growth curves of yeast cells producing various mutants of ProTa. Optical densities at 600 nm (OD600) of yeast cultures were deter-
mined, as described in Section 2. • , wild type; o , SIP, IIIV, K14W, K17E mutant; X, T105A mutant; ■, E80G, KIOIR double mutant; 
□, E80G mutant; ▲, KIOIR mutant; A, E44G, E50G double mutant; T , no ProTa (empty vector). B: Effect of mutations in ProTa on the 
yeast cell growth inhibition. The OD600 of yeast cultures, such as these shown on (A), were measured at 60 h postinoculation. The inactivation 
of ProTa (Y axis) by the indicated mutations is defined assuming the inhibition of cell growth by wild-type ProTa to be 100%. Hatched boxes 
indicate simultaneous effect of the double mutations E44G, E50G, and E80G, KIOIR. Mean values from three independent experiments are 
given. 
inhibitory effect [20,21]. ProTa NLS is known to reside in the 
carboxy-terminal half of the molecule [8,9]. Although it has 
not been precisely identified, a short basic block (residues 
101-104) similar to the canonical continuous NLS of SV40 
T antigen is likely to contribute to the active nuclear import of 
ProTa. In agreement with this model, our present analysis has 
identified several deleterious mutations located in or next to 
this basic sequence. However, based on our recent studies of 
yeast cell growth arrest by K87E ProTa mutant, we have 
hypothesized that ProTa NLS might be bipartite rather 
than continuous [21] (Table 2). 
To test this possibility, we studied the subcellular localiza-
tion of the above ProTa mutants to determine the NLS of this 
protein. For this purpose, we fused the wild-type ProTa and 
various ProTa mutants (K87E, KIOIR, A(101-109)) to the 
carboxy-terminus of GFP and expressed the chimeric genes 
under the control of the CMV promoter. In human 293 cells, 
subcellular distribution of hybrid proteins was examined by 
fluorescent microscopy. The human ProTa-GFP fusion was 
located exclusively in the nucleus (Fig. 3A), as expected from 
previous studies [9,10]. This suggests that the GFP fusions 
faithfully reflect the localization of native ProTa. Neither of 
the mutant ProTa fusion proteins were exclusively nuclear. 
The K87E and KIOIR mutants were found both in the nu-
cleus and the cytoplasm with the preference to the nucleus in 
the majority of cells (Fig. 3C,D, respectively). In all cases of 
nuclear localization the label was excluded from the nucleoli, 
in agreement to the previous data on the wild-type ProTa 
localization by indirect immunofluorescence [10]. Unlike the 
above ProTa point mutations that inactivate the NLS only 
partially, the deletion of the last nine amino acids (residues 
101-109) containing the second basic block resulted in the 
nuclear exclusion (Fig. 3B). 
The above results demonstrate that mutations in both parts 
of the putative bipartite NLS of human ProTa impair nuclear 
uptake of the protein, indicating that both basic blocks are 
necessary for efficient nuclear accumulation. Comparison of 
the carboxy-terminal region of human ProTa with that of 
closely related rat ProTa [29] demonstrates that at least 
some amino acid substitutions in the spacer region separating 
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Fig. 3. Localization of GFP-ProTa mutants in human 293 cells. 
Cells were transfected with the indicated expression constructs and 
fluorescent microscopy was performed, as described in Section 2. 
A: Wild-type ProTa. B: A(101-109) mutant. C: K87E mutant. 
D: K101R mutant. E: C-terminal ProTa peptide (residues 82-109). 
The transfections were done in parallel, and representative fields are 
shown for each transfection. Two independent experiments were 
performed, with similar results. Magnification: X710. 
these two blocks are tolerated. Interestingly, K101R mutation 
in the second basic block of the NLS impaired nuclear accu-
mulation of ProToc, indicating that a simple requirement for a 
basic amino acid in this position is not sufficient. Taken to-
gether, our results imply that the identified bipartite basic 
sequence represents the NLS of ProTa. To demonstrate that 
the putative NLS is not only necessary, but also sufficient to 
direct nuclear import of ProTa, the C-terminal ProTa peptide 
(residues 82-109) containing both basic regions was fused to 
GFP, and the localization of the hybrid protein was studied in 
human cells. This protein was found to be exclusively nuclear 
(Fig. 3E) which indicates that the residues 82-109 represent 
the NLS of ProTa. 
3.3. Additional functional determinant in human prothymosin a 
acting independently of nuclear import 
The above analysis suggests a correlation between the abil-
ity of human ProTa to accumulate in the nucleus of human 
cells and its ability to cause growth arrest in yeast cells. To 
further examine this correlation, we studied the same GFP-
tagged wild-type ProTa, mutant ProTa (K87E, K101R, 
A(101-109), T105A), and the NLS (residues 82-109) proteins 
in yeast 2805 cells. Subcellular localization of these proteins in 
yeast has several common features with the localization in 
human cells. GFP alone was diffusely spread throughout the 
whole cell (not shown), whereas GFP-ProTa fusion was lo-
calized exclusively in the nucleus (Fig. 4A). Mutations in both 
parts of the bipartite NLS caused the appearance of the pro-
tein in the cytoplasm, cytoplasmic localization being more 
pronounced for the K87E mutant (Fig. 4C). The K101R 
and A(101-109) mutants were both nuclear and cytoplasmic, 
with the preference to the nucleus in the majority of cells (Fig. 
4B,D, respectively). Interestingly, the GFP-NLS fusion pro-
tein was spread throughout the yeast cells (Fig. 4E), in con-
trast to the exclusive nuclear localization in human cells (Fig. 
3E). To check for degradation, resultant in the removal of 
ProTa residues from GFP, we performed SDS-PAGE of the 
Fig. 4. Localization of GFP-ProTa mutants in S. cerevisiae cells. 
Yeast cells harboring the indicated constructs were examined by 
fluorescent microscopy, as described in Section 2. A: Wild-type 
ProTa. B: A(101-109) mutant. C: K87E mutant. D: K101R 
mutant. E: C-terminal ProTa peptide (residues 82-109). F: T105A 
mutant. Production of the fusion proteins was controlled by the in-
ducible GAL10-CYC1 promoter. GFP-ProTa were synthesized in 
yeast cells by the overnight growth in the galactose-containing me-
dium. Magnification: X2200. 
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above fusion proteins produced in yeast. All hybrid proteins 
ran as a single band of the correct mobility, and therefore no 
degradation occured (not shown). Thus this NLS is sufficient 
for the nuclear targeting in human cells, but requires addi-
tional signals in yeast cells. This putative signal is apparently 
located upstream of the NLS, since the GFP-ProTa fusion 
was exclusively nuclear (Fig. 4A). 
Another interesting feature of human ProToc was revealed 
by T105A mutant. This mutant showed a markedly inacti-
vated phenotype when tested for yeast cell growth inhibition 
(Fig. 2). Since this mutation is located immediately next to the 
second basic block of the NLS, it appeared likely that the 
interference with the NLS could be responsible for this effect, 
by analogy with K87E and K101R mutations. However, 
T105A mutant turned out to be exclusively nuclear in yeast 
cells (Fig. 4F). Thus, it appears that ProToc inactivation in this 
case is not due to impaired nuclear targeting of this protein, 
but rather to the loss of the Thr residue in this position. It is 
therefore likely that an additional functional determinant lies 
next to or overlaps with the NLS, which might be directly 
responsible for yeast cell growth arrest by human ProToc. 
4. Discussion 
Until recently, no functional determinants in ProToc have 
been identified that could indicate possible mechanisms of its 
function. The primary structure of ProToc does not provide 
any hint about its mechanism of action. Its highly negative 
charge (p/-3.5, about half of the amino acid residues are 
dicarboxylic [2,3]) and the absence of aromatic and sulfur-
containing residues makes this 13 kDa protein unusual and 
may account for an apparent lack of secondary and higher 
order structures [8,30]. However, an important prediction was 
made about a short stretch of basic amino acids KKQK (res-
idues 101-104, see Table 2) located close to the carboxy ter-
minus of ProToc molecule. This motif was proposed to repre-
sent the NLS of ProToc, based on (i) similarity to the 
canonical continuous NLS such as that of SV40 T antigen 
[31], (ii) localization of the nuclear targeting determinant in 
the carboxy-terminal half of ProToc [9], and (iii) the inability 
of a truncated ProToc (residues 1-88) to accumulate in Xeno-
pus oocyte nuclei [8]. Consistent with these data, the human 
ProToc lacking the last nine carboxy-terminal residues, includ-
ing this putative NLS, failed to inhibit the yeast cell growth 
[20]. However, the residue K87, located 13 residues upstream 
from this putative NLS has been shown to be important for 
the inhibitory phenotype in yeast, leading us to propose that 
the NLS of ProToc might be bipartite [21], as exemplified by 
the NLS of nucleoplasmin [28,32]. In this study, we present 
mutational analysis of human ProToc aimed to delineate its 
functionally important determinants and, in particular, to de-
fine the structure of its NLS. Several mutations that inactivate 
the inhibitory phenotype of ProToc located in its carboxy ter-
minal part fell into or close to its putative NLS. This raised 
the possibility that, at least in some cases, a defect in ProToc 
functioning may be caused by its failure to enter the nucleus. 
To test this, we attempted to precisely determine the ProToc 
NLS and to study the effect of the above-mentioned muta-
tions on subcellular localization of ProToc. 
To localize ProToc in living cells, wild-type and mutant 
human ProToc were expressed as GFP fusions in human and 
yeast cells. Similar pattern of subcellular localization was ob-
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served in human cells and yeast cells for the wild-type ProToc 
and its mutants. Wild-type ProToc appeared to be exclusively 
nuclear and excluded from the nucleoli, in agreement with the 
previously reported data [9,10]. Mutations in both parts of the 
putative bipartite NLS of human ProToc (K87E; K101R) re-
sulted in a marked redistribution of the protein to the cyto-
plasm in both human and yeast cells, although the nuclear 
accumulation was still significant. This is expected for a bi-
partite NLS, where point mutations in each part of the NLS 
result in partially cytoplasmic localization of the originally 
nuclear protein, and only multiple mutations abrogate nuclear 
import completely [28]. Accordingly, deletion of the second 
basic stretch of the putative NLS (residues 101-109) resulted 
in cytoplasmic localization and exclusion from the nucleus of 
human cells. In yeast cells, this mutant appeared to be dis-
tributed between the cytoplasm and the nucleus. Thus, both 
stretches of basic residues are important for nuclear uptake of 
ProToc. These sequences are sufficient for nuclear import of 
ProToc since the GFP-(82-109) fusion protein was localized 
exclusively in the nucleus of human cells. Strikingly, in the 
heterologous yeast environment, the protein was spread 
evenly throughout the whole cell. This result was unexpected 
because the signals and mechanisms governing nuclear import 
of proteins are believed to be well conserved in mammalian 
and yeast cells [33]. Furthermore, a yeast SWI5 protein is 
known to possess a functional bipartite NLS that is similar 
to that of ProToc [34]. However, a minimal SWI5 fragment, 
identified as a NLS by nuclear targeting of a heterologous 
protein, contained extra SWI5 residues in addition to the bi-
partite basic sequences. Thus the NLS of human ProToc ap-
pears to be necessary but not sufficient for nuclear targeting of 
the protein in yeast cells. This implies that there is an addi-
tional signal(s) within the ProToc sequence required for the 
nuclear localization of this protein in yeast cells. 
Whereas the majority of deleterious mutations in ProToc 
affected its NLS, T105A mutation, though located immedi-
ately next to the NLS, has no effect on the nuclear import 
of ProToc. This result provides evidence of a novel function-
ally important determinant of ProToc. We speculate that 
Thr105 is directly involved in the inhibitory phenotype of 
ProToc. In summary, our results revealed two possible mech-
anisms responsible for releaving of the inhibitory action of 
human ProToc on yeast cell growth, which are represented 
by the two types of mutations: either by interference with 
the nuclear import, or by abrogating the inhibitory activity 
without affecting the nuclear import. 
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